Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B

Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving entecavir treatment remain unclear. We prospectively enrolled 529 patients (195 hepatitis B e antigen [HBeAg]-positive and 334...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Sci Rep
Main Authors: Peng, Cheng-Yuan, Lai, Hsueh-Chou, Su, Wen-Pang, Lin, Chia-Hsin, Chuang, Po-Heng, Chen, Sheng-Hung, Chen, Ching-Hsiang
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2017
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5318891/
https://ncbi.nlm.nih.gov/pubmed/28220833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep42879
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki